Evidence map›Paper›PMID 10327072›Full record

ArticleOncogene1999

The ATM protein is required for sustained activation of NF-kappaB following DNA damage.

B Piret, S Schoonbroodt, J Piette

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 178 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. DNA double-strand breaks: a potential therapeutic target for neurodegenerative diseases.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2019
    Review
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

B PiretLaboratory of Fundamental Virology and Immunology, University of Liège, CHU, Belgium.
S Schoonbroodt
J Piette
University of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cells lacking an intact ATM gene are hypersensitive to ionizing radiation and show multiple defects in the cell cycle-coupled checkpoints. DNA damage usually triggers cell cycle arrest through, among other things, the activation of p53. Another DNA-damage responsive factor is NF-kappaB. It is activated by various stress situations, including oxidative stress, and by DNA-damaging compounds such as topoisomerase poisons. We found that cells from Ataxia Telangiectasia patients exhibit a defect in NF-kappaB activation in response to treatment with camptothecin, a topoisomerase I poison. In AT cells, this activation is shortened or suppressed, compared to that observed in normal cells. Ectopic expression of the ATM protein in AT cells increases the activation of NF-kappaB in response to camptothecin. MO59J glioblastoma cells that do not express the DNA-PK catalytic subunit respond normally to camptothecin. These results support the hypothesis that NF-kappaB is a DNA damage-responsive transcription factor and that its activation pathway by DNA damage shares some components with the one leading to p53 activation.

Indexed as

DNA DamageI-kappa B ProteinsAdolescentAge FactorsAntineoplastic Agents, PhytogenicAtaxia TelangiectasiaAtaxia Telangiectasia Mutated ProteinsBrain NeoplasmsCamptothecinCell Cycle ProteinsCells, CulturedChildChild, PreschoolDNA-Activated Protein KinaseDNA-Binding ProteinsEnzyme Inhibitorsacetylleucyl-leucyl-norleucinalAntineoplastic Agents, PhytogenicAtaxia Telangiectasia Mutated ProteinsATM protein, humanCamptothecinCell Cycle ProteinsDNA-Activated Protein KinaseDNA-Binding ProteinsEnzyme InhibitorsI-kappa B ProteinsLeupeptinsNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanNuclear ProteinsPhosphoric Monoester HydrolasesPRKDC protein, humanProtease InhibitorsProteinsProtein Serine-Threonine KinasesRecombinant Fusion ProteinsTopoisomerase I InhibitorsTumor Necrosis Factor-alphaTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID10327072
OpenAlexW2316716290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.